StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 14 May 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html <p align="justify">Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.</p> <p><b>Conference Details: </b><br/>Date: Tuesday, May 19, 2026<br/>Company Presentation: 9:00 – 9:30AM EDT<br/>Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis<br/>Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank">here</a><br/><br/>Location: New York, http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html Thu, 14 May 2026 07:30:00 -0400 A.50216777 NVCT O.53485846 O.54516537 Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html <p align="justify">Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.</p> <p><b>Conference Details: </b><br/>Date: Tuesday, May 19, 2026<br/>Company Presentation: 9:00 – 9:30AM EDT<br/>Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis<br/>Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank">here</a><br/><br/>Location: New York, http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html Thu, 14 May 2026 07:30:00 -0400 A.50216777 NVCT O.53485846 O.54516537 Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html <p align="justify">Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.</p> <p><b>Conference Details: </b><br/>Date: Tuesday, May 19, 2026<br/>Company Presentation: 9:00 – 9:30AM EDT<br/>Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis<br/>Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank">here</a><br/><br/>Location: New York, http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html Thu, 14 May 2026 07:30:00 -0400 A.50216777 NVCT O.53485846 O.54516537 Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html <p align="justify">Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.</p> <p><b>Conference Details: </b><br/>Date: Tuesday, May 19, 2026<br/>Company Presentation: 9:00 – 9:30AM EDT<br/>Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis<br/>Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank">here</a><br/><br/>Location: New York, http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html Thu, 14 May 2026 07:30:00 -0400 A.50216777 NVCT O.53485846 O.54516537 Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html <p align="justify">Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.</p> <p><b>Conference Details: </b><br/>Date: Tuesday, May 19, 2026<br/>Company Presentation: 9:00 – 9:30AM EDT<br/>Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis<br/>Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank">here</a><br/><br/>Location: New York, http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html Thu, 14 May 2026 07:30:00 -0400 A.50216777 NVCT O.53485846 O.54516537 Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html <p align="justify">Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.</p> <p><b>Conference Details: </b><br/>Date: Tuesday, May 19, 2026<br/>Company Presentation: 9:00 – 9:30AM EDT<br/>Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis<br/>Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank">here</a><br/><br/>Location: New York, http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html Thu, 14 May 2026 07:30:00 -0400 A.50216777 NVCT O.53485846 O.54516537 Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html <p align="justify">Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.</p> <p><b>Conference Details: </b><br/>Date: Tuesday, May 19, 2026<br/>Company Presentation: 9:00 – 9:30AM EDT<br/>Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis<br/>Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank">here</a><br/><br/>Location: New York, http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html Thu, 14 May 2026 07:30:00 -0400 A.50216777 NVCT O.53485846 O.54516537 Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html <p align="justify">Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.</p> <p><b>Conference Details: </b><br/>Date: Tuesday, May 19, 2026<br/>Company Presentation: 9:00 – 9:30AM EDT<br/>Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis<br/>Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KFprPYTeCetfhkQuA6hCqmxfRM5HUH6X4-TePkAe9uVJSyZv2_GJPGfe7B64sl6naO9oeD5_JHjhyUGzKkREarDmnsg0i3Izvt9Qac_p4f23Y0HoRTh3a6CW8gIQ1F8XtuNgEml0WJSXHYg8CCDyQQ==" rel="nofollow" target="_blank">here</a><br/><br/>Location: New York, http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+To+Participate+in+the+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+NASDAQ/26489912.html Thu, 14 May 2026 07:30:00 -0400 A.50216777 NVCT O.53485846 O.54516537 Form 10-Q Nuvectis Pharma, Inc. For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Nuvectis+Pharma%2C+Inc.+++++For%3A+Mar+31/26431229.html si-local-file:///var/storage/secattach/20260505/26431229.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Nuvectis+Pharma%2C+Inc.+++++For%3A+Mar+31/26431229.html Tue, 05 May 2026 09:03:00 -0400 NVCT O.53485846 Form 10-Q Nuvectis Pharma, Inc. For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Nuvectis+Pharma%2C+Inc.+++++For%3A+Mar+31/26431229.html si-local-file:///var/storage/secattach/20260505/26431229.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Nuvectis+Pharma%2C+Inc.+++++For%3A+Mar+31/26431229.html Tue, 05 May 2026 09:03:00 -0400 NVCT O.53485846 Form 8-K Nuvectis Pharma, Inc. For: May 05 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nuvectis+Pharma%2C+Inc.+++++For%3A+May+05/26429963.html si-local-file:///var/storage/secattach/20260505/26429963.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nuvectis+Pharma%2C+Inc.+++++For%3A+May+05/26429963.html Tue, 05 May 2026 07:36:00 -0400 NVCT O.53485846 Form 8-K Nuvectis Pharma, Inc. For: May 05 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nuvectis+Pharma%2C+Inc.+++++For%3A+May+05/26429963.html si-local-file:///var/storage/secattach/20260505/26429963.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nuvectis+Pharma%2C+Inc.+++++For%3A+May+05/26429963.html Tue, 05 May 2026 07:36:00 -0400 NVCT O.53485846 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Press+Releases/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html <ul><li>NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US</li><li>NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy<br/><br/></li></ul> <p>FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.</p> <p>Ron http://www.streetinsider.com/Globe+Newswire/Nuvectis+Pharma%2C+Inc.+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26429903.html Tue, 05 May 2026 07:30:00 -0400 A.35552990 A.50216777 NVCT O.00074346 O.53485846 O.54516537 Form DEFA14A Nuvectis Pharma, Inc. http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Nuvectis+Pharma%2C+Inc.++++++++++++++++/26375543.html si-local-file:///var/storage/secattach/20260427/26375543.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Nuvectis+Pharma%2C+Inc.++++++++++++++++/26375543.html Mon, 27 Apr 2026 16:40:00 -0400 NVCT O.53485846